News / Asia

Patent Dispute Threatens Access to Cheap Drugs in India

Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only. Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
x
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
TEXT SIZE - +
Anjana Pasricha
NEW DELHI — A long running legal battle in India over drug patents could impact access to affordable, lifesaving drugs to millions of people across the globe. 

The case is being seen as a high stakes battle between drug companies supporting intellectual property rights and those who favor the production of cheap, generic drugs.   
Dr. Suniti Solomon has treated thousands of men and women suffering from HIV at her clinic in the southern city of Chennai since she detected India’s first AIDS infection 25 years ago. Affordable copies of brand name drugs produced by India’s booming generic drug industry have helped her patients enormously.   
 
“Earlier, when we did not have generic drugs, maybe one or two percent of my patients could afford the drugs from abroad," Solomon said. "Now, 60 to 70 percent can easily afford at least the first line drugs which keep them alive for maybe ten years or longer.”
 
Like the patients in Chennai, these generic drugs are a lifeline for millions of people in Africa and other developing countries.
 
Many of them are not aware of it, but a case pending before the Indian Supreme Court could have a far reaching impact on their access to these inexpensive drugs. 

It involves a legal challenge by Swiss pharmaceutical company Novartis to India’s refusal to grant a patent for a medicine used to treat leukemia. It has been winding its way through the Indian courts for almost six years. Final arguments will be heard next month.  
 
India denied a patent for Gleevec saying that it is not a new medicine but a salt formulation of a known drug. India does not allow companies to patent modifications of an old medicine unless its efficacy is significantly improved.
 
Forty countries, including the United States, China and Russia, have granted a patent for Gleevec. But in India, its generic version is being produced at a fraction of the cost.
 
Novartis says it is seeking clarity on how innovation by the drug industry will be protected in India. Ranjit Shahani, who heads the India operations of Novartis, says inadequate patent protection will discourage innovators.  
 
“The long road to innovation research is fraught with risks and huge costs," Shahani said. "Only one out of ten thousand experimental compounds in development will reach the marketplace and the cost is between one to two billion dollars for each medicine approved. A successful molecule that makes it as a drug needs to pay for thousands of those molecules that fail.”
 
The case has attracted international attention. The multinational drug industry sees the Indian law as a way of circumventing patent rights and wants more stringent standards.
 
However, supporters of India’s patent law say that it prevents a practice called “evergreening,” in which drug companies get new patents by making minor changes to older ones and stave off generic competition.
 
Leena Menghaney, a lawyer with Doctors Without Borders in New Delhi, calls it a test case.   
 
“If Novartis wins, it can have a huge chilling effect on generic production. Once patenting standards are lowered, that means more patents are granted on drugs, that means less number of drugs generic companies will be able to manufacture. So it has implications across the board for all essential medicines, particularly for HIV,” Mengheny said.
 
Health activists fear that a ruling in favor of Novartis may drastically reduce the global supply of inexpensive, generic drugs being used to treat people suffering from deadly diseases. They say if costs rise greatly, voluntary groups across the world will have to significantly scale down programs assisting patients who cannot afford lifesaving medicines.
 
One such patient is a 23-year-old student in Mumbai, Siddhesh Tilekar. Since he was diagnosed with cancer about three years ago, he gets drugs from a local cancer support group.
 
“We cannot afford that much of cost," Tilekar said. "If my family spends on my medicine, it is very difficult for us to survive.”
 
Multinational drug companies are worried about other provisions in India’s patent law.

Earlier this year, India allowed a domestic company to manufacture an expensive anti-cancer drug developed by Bayer Corporation using a rule under which a license can be granted if a drug is not available at a “reasonably affordable price.”  
 
According to Ranjit Shahani at Novartis, protecting patents is critical.
 
“The reality is without patents there will be no new drugs and without new drugs there will be no generics," he said. "So if innovation is not protected, it is the patient who will be the ultimate loser.”
 
Lawyers say there are also worries that India’s patent laws could become a model for other developing countries, limiting the multinational drug industry’s access to these fast-growing markets.

You May Like

Multimedia Anti-Keystone XL Protests Continue

Demonstrators are worried about pipeline's effect on climate change, their traditional way of life, health and safety More

Thailand's Political Power Struggle Continues

Court gave Prime Minister Yingluck Shinawatra until May 2 to prepare her defense over abuse of power charges but uncertainty remains over election timing More

Malaysia Plane Search Tests Limits of Ocean Mapping Technology

Expert tells VOA existing equipment’s maximum operating depth is around 6 kilometers as operation continues on ocean bed for any trace of MH370 More

This forum has been closed.
Comment Sorting
Comments
     
by: patent litigation from: Mexico
July 23, 2012 4:01 AM
Compulsory licensing is a contemporary necessity, and I'm glad to see countries from Australian to China implementing this model. I, for one, am heartened not only by the Indian Patent Office's recent decision to grant a compulsory license, but also by the further news that India now has plans to distribute some life-saving drugs for free. That -- and not gouging suffering patients at every possible opportunity -- seems to me to be the epitome of corporate responsibility.
http://www.generalpatent.com/blog


by: C Karen Stopford from: Connecticut
July 21, 2012 8:38 AM
What the pharmaceutical companies are saying is patently (no pun intended) false. Not every country lives by the American ethos of "profit at all costs." Why, believe it or not, there are some places in the world where human life has a value greater than a big credit limit. And innovation occurs in these places because people are respected, valued, allowed to explore and learn and satisfy their curiosity, and because people want to help other people. In fact, that's where most innovations come from. Not in America, of course - but elsewhere. Our system is cruel, unjust, immoral and unethical - and we will bully every other country in the world to do as we do - or else. Let 'em die! We need a profit!

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Pet Kangaroo Helps Spread Environmental Messagei
X
Penelope Poulou
April 22, 2014 5:53 PM
Children’s author Julia Heckathorn travels the world to learn about different ecosystems and endangered animals. She pours her knowledge into children’s books, hoping the next generation will right the environmental wrongs of our times. As in many children's books, the main character in Heckathorn's stories is an animal. Unlike those other characters, though, this one is real - a kangaroo, that lives in the author’s backyard. VOA’s Penelope Poulou has more.
Video

Video Pet Kangaroo Helps Spread Environmental Message

Children’s author Julia Heckathorn travels the world to learn about different ecosystems and endangered animals. She pours her knowledge into children’s books, hoping the next generation will right the environmental wrongs of our times. As in many children's books, the main character in Heckathorn's stories is an animal. Unlike those other characters, though, this one is real - a kangaroo, that lives in the author’s backyard. VOA’s Penelope Poulou has more.
Video

Video Pro-Russian Separatists Plan 'Federalization Referendum' in Eastern Ukraine

Pro-Russian separatists in eastern Ukraine say they plan to move forward next month with a referendum vote for greater autonomy, despite the Geneva agreement reached with Russia, the U.S. and Ukraine to end the political conflict. VOA's Brian Padden reports from the city of Donetsk in Eastern Ukraine.
Video

Video Pope Francis Hopes Dual Canonizations Will Reconcile Church

On April 27, two popes - John the XXIII and John Paul II - will be made saints in a ceremony at St. Peter’s Square. VOA religion correspondent Jerome Socolovsky says the dual canonization is part of the current pope’s program to reconcile liberals and conservatives in the Roman Catholic Church.
Video

Video In Capturing Nature's Majesty, Film Makes Case for Its Survival

French filmmaker Luc Jacquet won worldwide acclaim for his 2005 Academy Award-winning documentary "March of the Penguins". Now Jacquet is back with a new film that takes movie-goers deep into the heart of a tropical rainforest - not only to celebrate its grandeur, but to make the case for its survival. VOA's Rosanne Skirble reports.
Video

Video Boston Marathon Bittersweet for Many Runners

Monday's running of the Boston Marathon was bittersweet for many of the 36,000 participants as they finished the run that was interrupted by a double bombing last year. Many gathered along the route paid respect to the four people killed as a result of two bombings near the finish line. VOA's Carolyn Presutti returned to Boston this year to follow two runners, forever changed because of the crimes.
Video

Video International Students Learn Film Production in World's Movie Capital

Hollywood - which is part of Los Angeles - is the movie capital of the world, and many aspiring filmmakers go there in hopes of breaking into the movie business. Mike O'Sullivan reports that regional universities are also a magnet for students who hope to become producers or directors.
Video

Video Pacific Rim Trade Deal Proves Elusive

With the U.S.-led war in Iraq ended and American military involvement in Afghanistan winding down, President Barack Obama has sought to pivot the country's foreign policy focus towards Asia. One aspect of that pivot is the negotiation of a free-trade agreement among 12 Pacific Rim nations. But as Obama leaves this week on a trip to four Asian countries he has found it very difficult to complete the trade pact. VOA's Ken Bredemeier has more from Washington.
Video

Video Autistic Adults Face Housing, Job Challenges

Many parents of children with disabilities fear for the future of their adult child. It can be difficult to find services to help adults with disabilities - physical, mental or emotional - find work or live on their own. The mother of an autistic boy set up a foundation to advocate for the estimated 1.2 million American adults with autism, a developmental disorder that causes communication difficulties and often social difficulties. VOA's Faiza Elmasry reports.
AppleAndroid